Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
April 17, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that patient enrollment has been completed in the Company’s Phase 2 clinical study of...
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 08, 2024 07:00 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., March 08, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Leerink Partners Global...
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
March 05, 2024 10:30 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that Anthony S. Marucci, President and Chief Executive Officer will participate in an...
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 05, 2024 10:10 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public...
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
February 29, 2024 21:14 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an upsized underwritten public offering of...
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
February 28, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it is proposing to offer and sell, subject to market...
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
February 26, 2024 07:01 ET
|
Celldex Therapeutics, Inc.
- Phase 3 CSU studies expected to initiate in summer 2024 -- Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 --...
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
February 24, 2024 14:05 ET
|
Celldex Therapeutics, Inc.
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid...
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 06, 2024 16:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th...
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
February 05, 2024 08:01 ET
|
Celldex Therapeutics, Inc.
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company’s Phase 2 clinical trial of...